“The paralyzing viral outbreak that has swept the planet, costing trillions in output and gumming up the wheels of the global economy has also created a confluence of events so very favorable for biotechs that it will continue to push the sector higher up the golden arc,” declares the author of today’s article, which lays out the favorable macro environment for biotechs that is likely to persist beyond 2020 – and identifies a number of promising plays. For more, CLICK HERE.